David C Klonoff

List of Publications by Year
in descending order

109 papers	3,706 citations	159585 30 h-index	149698 56 g-index
117 all docs	117 docs citations	117 times ranked	4413 citing authors

#	Article	IF	Citations
1	Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. Journal of Diabetes Science and Technology, 2020, 14, 813-821.	2.2	535
2	Continuous glucose monitoring: A review of the technology and clinical use. Diabetes Research and Clinical Practice, 2017, 133, 178-192.	2.8	192
3	Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care, 2018, 41, 1579-1589.	8.6	175
4	The Surveillance Error Grid. Journal of Diabetes Science and Technology, 2014, 8, 658-672.	2.2	125
5	Continuous glucose monitoring systems - Current status and future perspectives of the flagship technologies in biosensor research -. Biosensors and Bioelectronics, 2021, 181, 113054.	10.1	114
6	Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors. Diabetes Care, 2018, 41, 1681-1688.	8.6	112
7	Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile. Journal of Diabetes Science and Technology, 2013, 7, 562-578.	2.2	104
8	Consensus Statement on Inpatient Use of Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, 2017, 11, 1036-1044.	2.2	99
9	Overview of Fluorescence Glucose Sensing: A Technology with a Bright Future. Journal of Diabetes Science and Technology, 2012, 6, 1242-1250.	2.2	91
10	Implementation of Continuous Glucose Monitoring in the Hospital: Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic. Journal of Diabetes Science and Technology, 2020, 14, 822-832.	2.2	86
11	Letter to the Editor: COVID-19 in patients with diabetes: Risk factors that increase morbidity. Metabolism: Clinical and Experimental, 2020, 108, 154224.	3.4	83
12	Technical Aspects of the Parkes Error Grid. Journal of Diabetes Science and Technology, 2013, 7, 1275-1281.	2.2	81
13	Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline. Journal of Diabetes Science and Technology, 2020, 14, 1035-1064.	2.2	77
14	Biological and epidemiological trends in the prevalence and mortality due to outbreaks of novel coronavirus COVID-19. Journal of King Saud University - Science, 2020, 32, 2495-2499.	3.5	77
15	Fog Computing and Edge Computing Architectures for Processing Data From Diabetes Devices Connected to the Medical Internet of Things. Journal of Diabetes Science and Technology, 2017, 11, 647-652.	2.2	71
16	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	2.2	69
17	Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis. Diabetes Care, 2021, 44, 578-585.	8.6	65
18	Effect of environmental pollutants PM-2.5, carbon monoxide, and ozone on the incidence and mortality of SARS-COV-2 infection in ten wildfire affected counties in California. Science of the Total Environment, 2021, 757, 143948.	8.0	64

#	Article	IF	Citations
19	Impact of lockdown on COVID-19 prevalence and mortality during 2020 pandemic: observational analysis of 27 countries. European Journal of Medical Research, 2020, 25, 56.	2.2	63
20	Wearable physiological systems and technologies for metabolic monitoring. Journal of Applied Physiology, 2018, 124, 548-556.	2.5	60
21	A randomized, multicentre trial evaluating the efficacy and safety of fastâ€acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes, Obesity and Metabolism, 2019, 21, 961-967.	4.4	59
22	Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia, 2020, 63, 698-710.	6.3	58
23	Cybersecurity for Connected Diabetes Devices. Journal of Diabetes Science and Technology, 2015, 9, 1143-1147.	2.2	55
24	Assisted Monitoring of Blood Glucose: Special Safety Needs for a New Paradigm in Testing Glucose. Journal of Diabetes Science and Technology, 2010, 4, 1027-1031.	2.2	53
25	Smart Pens Will Improve Insulin Therapy. Journal of Diabetes Science and Technology, 2018, 12, 551-553.	2.2	53
26	ENDOCRINOLOGY IN THE TIME OF COVID-19: Remodelling diabetes services and emerging innovation. European Journal of Endocrinology, 2020, 183, G67-G77.	3.7	48
27	The Expanding Role of Real-World Evidence Trials in Health Care Decision Making. Journal of Diabetes Science and Technology, 2020, 14, 174-179.	2.2	44
28	Behavioral Theory: The Missing Ingredient for Digital Health Tools to Change Behavior and Increase Adherence. Journal of Diabetes Science and Technology, 2019, 13, 276-281.	2.2	42
29	A Simplified Approach Using Rate of Change Arrows to Adjust Insulin With Real-Time Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, 2017, 11, 1063-1069.	2.2	34
30	Hemoglobinopathies and Hemoglobin A1c in Diabetes Mellitus. Journal of Diabetes Science and Technology, 2020, 14, 3-7.	2.2	34
31	Standardization process of continuous glucose monitoring: Traceability and performance. Clinica Chimica Acta, 2021, 515, 5-12.	1.1	34
32	Overcoming Barriers to Adoption of Digital Health Tools for Diabetes. Journal of Diabetes Science and Technology, 2018, 12, 3-6.	2.2	32
33	Open Source Closed-Loop Insulin Delivery Systems: A Clash of Cultures or Merging of Diverse Approaches?. Journal of Diabetes Science and Technology, 2018, 12, 1223-1226.	2.2	32
34	A Review of Continuous Glucose Monitoring-Based Composite Metrics for Glycemic Control. Diabetes Technology and Therapeutics, 2020, 22, 613-622.	4.4	30
35	Continuous Glucose Monitoring in the Hospital. Endocrinology and Metabolism, 2021, 36, 240-255.	3.0	30
36	Products for Monitoring Glucose Levels in the Human Body With Noninvasive Optical, Noninvasive Fluid Sampling, or Minimally Invasive Technologies. Journal of Diabetes Science and Technology, 2022, 16, 168-214.	2.2	30

#	Article	IF	Citations
37	Real-World Evidence Should Be Used in Regulatory Decisions About New Pharmaceutical and Medical Device Products for Diabetes. Journal of Diabetes Science and Technology, 2019, 13, 995-1000.	2.2	28
38	A Review of Blood Glucose Monitor Accuracy. Diabetes Technology and Therapeutics, 2018, 20, 843-856.	4.4	26
39	Implementation of Basalâ€“Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics, 2019, 21, 273-285.	4.4	26
40	Telemedicine for Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 3-5.	2.2	25
41	Insulin Pump Occlusions: For Patients Who Have Been Around the (Infusion) Block. Journal of Diabetes Science and Technology, 2017, 11, 451-454.	2.2	23
42	Digital Health Interventions for Diabetes: Everything to Gain and Nothing to Lose. Diabetes Spectrum, 2019, 32, 226-230.	1.0	23
43	PRIDE Statement on the Need for a Moratorium on the CMS Plan to Cite Hospitals for Performing Point-of-Care Capillary Blood Glucose Monitoring on Critically Ill Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3607-3612.	3.6	21
44	Consensus Statement on Use of Continuous Subcutaneous Insulin Infusion Therapy in the Hospital. Journal of Diabetes Science and Technology, 2018, 12, 880-889.	2.2	21
45	Digital Diabetes Data and Artificial Intelligence: A Time for Humility Not Hubris. Journal of Diabetes Science and Technology, 2019, 13, 123-127.	2.2	20
46	Continuous Ketone Monitoring Consensus Report 2021. Journal of Diabetes Science and Technology, 2022, 16, 689-715.	2.2	18
47	The Need for Data Standards and Implementation Policies to Integrate CGM Data into the Electronic Health Record. Journal of Diabetes Science and Technology, 2023, 17, 495-502.	2.2	18
48	Continuous Ketone Monitoring: A New Paradigm for Physiologic Monitoring. Journal of Diabetes Science and Technology, 2021, 15, 193229682110098.	2.2	17
49	Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes. Diabetes Care, 2019, 42, 2154-2157.	8.6	16
50	Supporting Good Intentions With Good Evidence: How to Increase the Benefits of Diabetes Social Media. Journal of Diabetes Science and Technology, 2019, 13, 974-978.	2.2	16
51	The Diabetes Technology Society Green Diabetes Initiative. Journal of Diabetes Science and Technology, 2020, 14, 507-512.	2.2	16
52	Engineered fungus derived FAD-dependent glucose dehydrogenase with acquired ability to utilize hexaammineruthenium(III) as an electron acceptor. Bioelectrochemistry, 2018, 123, 62-69.	4.6	15
53	Standards for Medical Device Cybersecurity in 2018. Journal of Diabetes Science and Technology, 2018, 12, 743-746.	2.2	14
54	Telemedicine for Diabetes After the COVID-19 Pandemic: We Canâ€™t Put the Toothpaste Back in the Tube or Turn Back the Clock. Journal of Diabetes Science and Technology, 2020, 14, 741-742.	2.2	14

#	Article	IF	Citations
55	Effect of insulin degludec versus insulin glargine <scp>U100</scp> on time in range: <scp>SWITCH PRO</scp>, a crossover study of basal insulinâ€treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes, Obesity and Metabolism, 2021, 23, 2572-2581.	4.4	14
56	New Opportunities for Digital Health to Thrive. Journal of Diabetes Science and Technology, 2019, 13, 159-163.	2.2	13
57	The Launch of the iCoDE Standard Project. Journal of Diabetes Science and Technology, 2022, 16, 887-895.	2.2	13
58	Digital Diabetes Communication. Journal of Diabetes Science and Technology, 2016, 10, 1003-1005.	2.2	12
59	A Milestone in Point of Care Capillary Blood Glucose Monitoring of Critically Ill Hospitalized Patients. Journal of Diabetes Science and Technology, 2018, 12, 1095-1100.	2.2	12
60	Digital Connectivity: The Sixth Vital Sign. Journal of Diabetes Science and Technology, 2022, 16, 1303-1308.	2.2	12
61	The First Recall of a Diabetes Device Because of Cybersecurity Risks. Journal of Diabetes Science and Technology, 2019, 13, 817-820.	2.2	11
62	The Need for Accuracy in Hemoglobin A1c Proficiency Testing: Why the Proposed CLIA Rule of 2019 Is a Step Backward. Journal of Diabetes Science and Technology, 2019, 13, 424-427.	2.2	11
63	An Opportunity to Increase the Benefit of CGM Usage: The Need to Train the Patients Adequately. Journal of Diabetes Science and Technology, 2020, 14, 983-986.	2.2	11
64	The Need for Precision Medicine to be Applied to Diabetes. Journal of Diabetes Science and Technology, 2020, 14, 1122-1128.	2.2	10
65	Pharmacoadherence: An Opportunity for Digital Health to Inform the Third Dimension of Pharmacotherapy for Diabetes. Journal of Diabetes Science and Technology, 2021, 15, 177-183.	2.2	10
66	Advances in Insulin Pump Infusion Sets Symposium Report. Journal of Diabetes Science and Technology, 2021, 15, 705-709.	2.2	10
67	User and Healthcare Professional Perspectives on Do-It-Yourself Artificial Pancreas Systems: A Need for Guidelines. Journal of Diabetes Science and Technology, 2022, 16, 224-227.	2.2	9
68	Excess Mortality in COVID-19-Positive Versus COVID-19-Negative Inpatients With Diabetes: A Nationwide Study. Diabetes Care, 2021, 44, e169-e170.	8.6	8
69	Finding Real Value From Digital Diabetes Health: Is Digital Health Dead or in Need of Resuscitation?. Journal of Diabetes Science and Technology, 2018, 12, 911-913.	2.2	7
70	Postmarket Surveillance of Blood Glucose Monitor Systems Is Needed for Safety of Subjects and Accurate Determination of Effectiveness in Clinical Trials of Diabetes Drugs and Devices. Journal of Diabetes Science and Technology, 2019, 13, 419-423.	2.2	7
71	Green Diabetes Summit 2021. Journal of Diabetes Science and Technology, 2022, 16, 233-247.	2.2	7
72	Evaluating the usability and safety of the semaglutide singleâ€dose penâ€injectors through summative (human factors) usability testing. Journal of Diabetes Investigation, 2021, 12, 978-987.	2.4	6

#	Article	IF	Citations
73	Semaglutide singleâ€dose penâ€injector: Post hoc analysis of summative usability testing for weight management. Diabetes, Obesity and Metabolism, 2021, 23, 2590-2594.	4.4	6
74	The End of the Road for the YSI 2300 Analyzer: Where Do We Go Now?. Journal of Diabetes Science and Technology, 2020, 14, 595-600.	2.2	5
75	Automated Insulin Dosing Systems or Automated Insulin Delivery Systems? It is Time for Consistency. Journal of Diabetes Science and Technology, 2021, 15, 211-213.	2.2	5
76	Now Is the Time for a Security and Safety Standard for Consumer Smartphones Controlling Diabetes Devices. Journal of Diabetes Science and Technology, 2017, 11, 870-873.	2.2	4
77	Is Digital Health for Diabetes in an Investment Bubble?. Journal of Diabetes Science and Technology, 2020, 14, 165-169.	2.2	4
78	Diagnosing diabetes mellitus from smartphone-based vascular signals. Nature Reviews Endocrinology, 2020, 16, 681-682.	9.6	4
79	The Coronavirus 2019 Pandemic and Diabetes: An International Perspective. Journal of Diabetes Science and Technology, 2020, 14, 703-704.	2.2	4
80	The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial. Journal of Diabetes Science and Technology, 2021, 15, 636-645.	2.2	4
81	The Need for Sharps Waste Disposal Guidelines for Commercial Airports. Journal of Diabetes Science and Technology, 2022, 16, 1370-1375.	2.2	4
82	The Diabetes Technology Society Green Declaration. Journal of Diabetes Science and Technology, 2022, 16, 215-217.	2.2	4
83	Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine <scp>U300</scp> in people with type 2 diabetes: A post hoc analysis of the <scp>CONCLUDE</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 332-336.	4.4	4
84	Response to Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care 2018;41:1579â€“1589. Diabetes Care, 2019, 42, e66-e67.	8.6	3
85	Barriers and Solutions to a Recently Noted Failure of Diabetes Care Outcomes to Improve From 2005 to 2016 in the United States. Journal of Diabetes Science and Technology, 2020, 14, 189-190.	2.2	3
86	Predictors of Time-to-Repeat Point-of-Care Glucose Following Hypoglycemic Events in Hospitalized Patients. Journal of Diabetes Science and Technology, 2020, 14, 526-534.	2.2	3
87	User experiences with second-generation 32-gauge Ã— 4â€‰mm vs. thinner comparator pen needles: prospective randomized trial. Current Medical Research and Opinion, 2020, 36, 1591-1600.	1.9	3
88	Diabetes Technology and Waste: A Complex Story. Journal of Diabetes Science and Technology, 2021, , 193229682110223.	2.2	3
89	Antioxidant-Induced Pseudohyperglycemia Due to Interference of Measurements by Blood Glucose Monitors. Journal of Diabetes Science and Technology, 2021, 15, 1404-1405.	2.2	3
90	1021-P: HbA1c Levels and Rates of Hypoglycemia with Insulin Degludec U200 and Insulin Glargine U300 Stratified by Renal Function Subgroups: Post Hoc Analysis from the CONCLUDE Trial. Diabetes, 2020, 69, .	0.6	3

#	Article	IF	Citations
91	111-LB: Hepatic Insulin Delivery to Minimize Hypoglycemic Events in Persons with Type 1 Diabetes: The OPTI-1 Study. Diabetes, 2020, 69, .	0.6	3
92	Noninvasive Glucose Monitoring: In God We Trustâ€"All Others Bring Data. Journal of Diabetes Science and Technology, 2021, 15, 1211-1215.	2.2	3
93	Reduced hypoglycaemia using liverâ€targeted insulin in individuals with type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1762-1769.	4.4	3
94	Input of Patients for New Diabetes Technology Products. Journal of Diabetes Science and Technology, 2021, 15, 983-985.	2.2	2
95	A Gut-Centric Model of Metabolic Homeostasis. Journal of Diabetes Science and Technology, 2021, , 193229682110445.	2.2	2
96	Diabetes Technology Meeting 2021. Journal of Diabetes Science and Technology, 2022, , 193229682210902.	2.2	2
97	The FDA Pilot Accreditation Scheme for Conformity: Will It Pertain to Cybersecurity of Diabetes Devices?. Journal of Diabetes Science and Technology, 2021, 15, 535-538.	2.2	1
98	Diabetes Technology Meeting 2020. Journal of Diabetes Science and Technology, 2021, 15, 916-960.	2.2	1
99	Treating an Unconscious Patient With Diabetes Wearing a Device Attached to Their Body. Journal of Diabetes Science and Technology, 2022, 16, 583-586.	2.2	1
100	A New Digital Point-of-Care Tool With Advanced Blood Glucose Measuring Technology. Journal of Diabetes Science and Technology, 2022, , 193229682210927.	2.2	1
101	Response to Comment on Umpierrez and Klonoff. Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital. Diabetes Care 2018;41:1579â€"1589. Diabetes Care, 2019, 42, e15-e15.	8.6	0
102	The Need to Change Regulatory Evaluation of Hypoglycemia in Trials of Diabetes Treatments. Journal of Diabetes Science and Technology, 2020, 14, 987-989.	2.2	0
103	Regarding a successful treatment with artificial pancreas for a patient who attempted suicide using a highâ€dose insulin s.c. injection. Acute Medicine & Surgery, 2020, 7, e567.	1.2	0
104	Benefits of Conformity Assessment for Cybersecurity Standards of Diabetes Devices and Other Medical Devices. Journal of Diabetes Science and Technology, 2021, 15, 193229682110181.	2.2	0
105	Clinical Trials of COVID-19 Therapies Should Account for Diabetes and Hyperglycemia. Journal of Diabetes Science and Technology, 2021, 15, 1181-1187.	2.2	0
106	The Availability of Sharps Disposal Bins: A Survey of Airports in California. Journal of Diabetes Science and Technology, 2021, , 193229682110398.	2.2	0
107	Breakthrough technology for in-hospital glucose monitoring. Lancet Diabetes and Endocrinology,the, 2022, , .	11.4	0
108	Trimetazidine Blocks Lipid Oxidationâ€"Should it be Repurposed for Prevention and Treatment of Diabetic Ketoacidosis?. Journal of Diabetes Science and Technology, 0, , 193229682211001.	2.2	0

#	Article	IF	Citations
109	Retained Diabetes Devicesâ€"A Literature Review. Journal of Diabetes Science and Technology, 0, , 193229682211058.	2.2	0